Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 236-752-3 | CAS number: 13474-25-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Remarks:
- combined repeated dose and reproduction / developmental screening
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 2012-02-09 and 2013-05-21
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP-conform study in accordance to OECD guideline and US EPA guideline; for read-across justification, please refer to section 13.
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 013
- Report date:
- 2013
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- 1996
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: EPA OPPTS 870.3650 (Combined Repeated Dose Toxicity Study With the Reproduction/Developmental Toxicity Screening Test) 2000
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- 3-methyl-1-vinyl-1H-imidazolium methyl sulphate
- EC Number:
- 247-832-2
- EC Name:
- 3-methyl-1-vinyl-1H-imidazolium methyl sulphate
- Cas Number:
- 26591-72-0
- Molecular formula:
- C6H9N2.CH3O4S
- IUPAC Name:
- 3-methyl-1-vinyl-2,3-dihydro-1H-imidazol-1-ium methyl sulfate
- Test material form:
- other: solid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Research Models and Services, Germany GmbH
- Age at study initiation: 11-12 weeks
- Weight at study initiation: Male animals: 339.0 g - 372.4 g, Female animals: 191.1 g - 225.1 g
- Housing: individually in Makrolon type M III cages
- Diet: ad libitum, Kliba maintenance diet mouse/rat “GLP” meal (Provimi Kliba SA, Kaiseraugst, Switzerland)
- Water: ad libitum
- Acclimation period: 8 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24
- Humidity (%): 30-70
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS: For the preparation of the administration solutions the test substance was weighed in a calibrated beaker depending on the dose group, topped up with drinking water and subsequently intensely mixed with a magnetic stirrer until it was completely dissolved. The analytical results indicated that the test substance is stable in drinking water over a period of 7 days.
DIET PREPARATION
- Rate of preparation of diet (frequency): at the beginning of the administration period and thereafter in intervals - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The sample preparation were analytically verified by using HPLC method coupled with a DAD. Therefore, approx. 0.05 g of the test substance was dissolved to 100 mL usind drinking water. All determined concentrations were in the range between 90% and 110% of the nominal concentration, demonstrationg the correctness of the preparations.
- Duration of treatment / exposure:
- females: 49 days
males: 34 days - Frequency of treatment:
- once daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
100, 300, 1000 mg/kg bw/d
Basis:
nominal in water
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Positive control:
- no data
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: at least once daily
- Cage side observations checked: any signs of morbidity, pertinent behavioral changes and signs of overt toxicity
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: once prior to the first administration and at weekly intervals during the administration period
BODY WEIGHT: Yes
- Time schedule for examinations: once a week
FOOD CONSUMPTION: Yes
- once a week
WATER CONSUMPTION: not examined
OPHTHALMOSCOPIC EXAMINATION: not examined
HAEMATOLOGY: Yes
- Time schedule for collection of blood: at the end of the treatment period
- Anaesthetic used for blood collection: Yes (Isoflurane)
- Animals fasted: Yes
- How many animals: 5
- Parameters checked: Leukocyte count (WBC), Erythrocyte count (RBC), Hemoglobin (HGB), Hematocrit (HCT), Mean corpuscular volume (MCV), Mean corpuscular hemoglobin (MCH), Mean corpuscular hemoglobin concentration (MCHC), Platelet count (PLT), Differential blood count, Reticulocytes. Furthermore clotting tests were performed (parameter checked: Prothrombin time (Hepato Quick’s test) (HQT)).
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: at the end of the treatment period
- Anaesthetic used for blood collection: Yes (Isoflurane)
- Animals fasted: Yes
- How many animals: 5
- Parameters checked: Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), γ-Glutamyltransferase (GGT), Sodium, Potassium, Chloride, Inorganic phosphate, Calcium, Urea, Creatinine, Glucose, Total bilirubin, Total protein, Albumin, Globulins, Triglycerides, Cholesterol, Bile acids
URINALYSIS: Yes
- Time schedule for collection of urine: overnight (at the end of the treatment period)
- Metabolism cages used for collection of urine: Yes (withdrawal of food and water)
- Animals fasted: Yes
- Parameters checked: pH, protein, glucose, ketones, urobilinogen, bilirubin, blood, specific gravity, sediment, color, turbidity, volume
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: at the end of the adminstration period
- Dose groups that were examined: 5 males and 5 femles (with litter) per group
- Battery of functions tested: sensory activity, home cage observations, open field observations, motor activity - Sacrifice and pathology:
- - MORTALITY
- GROSS PATHOLOGY: Yes (adrenal glands, aorta, bone marrow (femur), brain, cecum, cervix, coagulating gland, colon, duodenum, eyes with optic nerve, esophagus, extraorbital lacrimal glands, epididymides, femur with knee joint, heart, ileum, jejunum, kidneys, larynx, liver, lungs, lymph nodes, mammary gland, nose, ovaries, oviducts, pancreas, parathyroid glands, pharynx, pituitary gland, prostate gland, rectum, salivary glands, sciatic nerve, seminal vesicles, skeletal muscle, spinal cord, spleen, sternum with marrow, stomach, testes, thymus, thyroid, glands, trachea, urinary bladder, uterus, vagina)
- HISTOPATHOLOGY: Yes (adrenal glands, all gross lesions, bone marrow (femur), brain, cecum, cervix, coagulating glands, colon, duodenum, epididymes, heart, ileum, jejunum, kidneys, liver, lungs, lymph nodes, ovaries, oviducts, prostate gland, peyer's patches, rectum, sciatic nerve, seminal vesicles) - Other examinations:
- - Organ weights: Epididymides, testes (in all animals sacrificed); adrenal glands, brain, heart, kidneys, liver, spleen, thymus (in 5 animals per sex/test group, females with litters only, same animals as used for clinical pathological examinations)
- Statistics:
- The following statistical tests were used (depending on the parameter): DUNNETT-test, KRUSKAL-WALLIS test, WILCOXON-test (one-side)
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY: No clinical signs or changes of general behavior, which may be attributed to the test substance, were detected in any male or female. Several male and female animals of dose group 3 (1000 mg/kg bw/d) showed salivation after treatment. This transient salivation for a few minutes immediately after each treatment was likely to be induced by the unpleasant taste of the test substance or by local irritation of the upper digestive tract. It is not considered to be a sign of systemic toxicity. There were no substance-related mortalities in any of the male and female parental animals in any of the groups. On premating day 12, one high dose F0 female (No. 137 - 1000 mg/kg body weight/day) was found dead after a gavage error.
BODY WEIGHT AND WEIGHT GAIN: comparable to the concurrent control group during the entire study period
FOOD CONSUMPTION: comparable to the concurrent control group during the entire study period
HAEMATOLOGY: No treatment-related changes among hematological parameters were observed. In males of test groups 2 and 3 (300 and 1000 mg/kg bw/d) absolute and relative eosinophil counts and additionally in males of test group 1 (100 mg/kg bw/d) relative eosinophil counts were increased. The values were within historical control ranges whereas the means of the control were at the low part of these ranges (absolute eosinophil counts: 0.07-0.18 Giga/L, relative eosinophil counts: 1.3-3.0 %). Therefore, these alterations were regarded as incidental and not treatment-related.
CLINICAL CHEMISTRY: In males of test group 2 (300 mg/kg bw/d) alanine aminotransferase (ALT) activities were lower, whereas in females of the same test group ALT activities were higher compared to controls. Additionally, in males of test group 2 (300 mg/kg bw/d) potassium values were lower compared to controls. All these values were changed not dose-dependently and therefore these alterations were regarded as incidental and not treatment-related. In males of test group 3 (1000 mg/kg bw/d) calcium levels were increased, but the means were within the historical control range (calcium: 2.49-2.76 mmol/L).
Therefore, this change was regarded as incidental and not treatment-related.
URINALYSIS: No treatment-related changes among urinalysis parameters were observed.
NEUROBEHAVIOUR: No test substance-related or spontaneous findings were observed in male and female animals of all test groups during the home cage observation as well as open field observations. Concerning the sensorimotor tests, no test substance-related findings in male and female animals of all test groups were observed. Any deviations from "zero values" were equally distributed between test substance-treated groups and controls or occurred in single animals only. Therefore, these observations were considered as being incidental. In addition, no treatment-related changes on motor activity data (summation of all intervals) was observed in the male and female animals of all dose groups in comparison to the concurrent control group. The statistically significantly decreased number of interrupted beams in high-dosed males (test group 3 - 1000 mg/kg bw/d) in interval 2, the statistically significantly increased number of interrupted beams in mid-dosed males (test group 2 - 300 mg/kg bw/d) in interval 6 and the statistically significantly increased number of interrupted beams in high-dosed females (test group 3) in interval 2 were considered as spontaneous in nature and not treatment related.
ORGAN WEIGHTS: When compared to the control group 0 (set to 100%), the mean relative and absolute liver weight was significantly increased in male animals of the high-dose group. All other mean relative and absolute weight parameters in males and all weight parameters in females did not show significant differences when compared to the control group 0. The increase in absolute and relative liver weights in test group 3 (1000 mg/kg bw/day) in male animals was considered to be treatment - related.
GROSS PATHOLOGY: One female animal that died showed a ruptured esophagus. All other findings occurred individually. They were considered to be incidental or spontaneous in origin and without any relation to treatment.
HISTOPATHOLOGY: NON-NEOPLASTIC: One animal showed rupture of the esophagus confirming the macroscopic diagnosis. All other findings occurred either individually or were biologically equally distributed over control and treatment groups. They were considered to be incidental or spontaneous in origin and without any relation to treatment.
HISTOPATHOLOGY: NEOPLASTIC: not examined
HISTORICAL CONTROL DATA: Yes
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: general, systemic toxicity (F0 generation)
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.